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A 63-year-old woman with stable angina under-
went percutaneous coronary intervention of
the left circumflex coronary artery (LCX) and
the first obtuse marginal branch (OM1) with
biolimus-eluting stents (BES) with the V-stenting
technique (Panels A and A′). Seven months later
due to recurrent angina repeat coronary angiog-
raphy was performed and revealed in-stent re-
stenosis in the proximal segments of both BES.
Subsequently, the OM1 lesion was dilated with
a paclitaxel drug-coated balloon. The LCX sten-
osis was treated with an everolimus eluting bior-
esorbable vascular scaffold (BVS) extending into
the proximal LCX segment (bioresorbable in
metallic stenting) (Panels B and B′). A proximal
edge dissection (Supplementary material online, Videos—OCT) was managed by implantation of another overlapping BVS in the proximal
LCX (Panels J, J′, K, and K′). Three months later the patient presented with recurrent chest pain. Coronary angiography documented
in-stent restenosis in the proximal OM1 (Panel C) that was treated by implantation of a zotarolimus-eluting stent (ZES) extending
from OM1 to the proximal LCX (Panel C′) covering the BVS (metallic in bioresorbable stenting).
Twenty-seven months after the first intervention the patient reported atypical angina. Because of her extensive history, she was dir-
ectly referred for coronary angiography, which showed all stents patent with excellent flow (Panel D). An optical coherence tomography
was performed (Supplementary material online, Videos), which confirmed complete endothelialization, no restenosis, and well-expanded
BVS in BES (Panels F and F′) as well as ZES in BVS (Panels H and H′).
Although these approaches need further evaluation through clinical trials, this case confirms the feasibility and efficacy of using metallic
in bioresorbable and bioresorbable in metallic stenting for the treatment of in-stent restenosis with excellent endothelialization as docu-
mented by optical coherence tomography.
Supplementary material is available at European Heart Journal online.
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